--- title: "Elon Musk’s Neuralink sparks BCI race in China" description: "Neuralink, founded by Elon Musk, is driving a surge in brain-computer interface (BCI) development in China, with startups like NeuroXess rapidly moving into human trials. NeuroXess, launched in 2021, " type: "news" locale: "en" url: "https://longbridge.com/en/news/276460367.md" published_at: "2026-02-20T15:32:08.000Z" --- # Elon Musk’s Neuralink sparks BCI race in China > Neuralink, founded by Elon Musk, is driving a surge in brain-computer interface (BCI) development in China, with startups like NeuroXess rapidly moving into human trials. NeuroXess, launched in 2021, is already testing implants in patients. China's government has classified BCIs as a strategic sector, aiming for globally competitive companies by 2030. Since February last year, at least 10 clinical trials for invasive brain chips have started in China, reflecting increased investment interest in the field. Neuralink's visibility has energized competitors, highlighting the global race in BCI technology. Neuralink, founded by Elon Musk, is helping spark a surge of brain-computer interface (BCI) development in China, where startups are moving quickly into human trials with strong state backing. One of the most prominent is NeuroXess, which launched in 2021 and is already testing implants in patients. Neuralink’s clinical work and public demonstrations have drawn worldwide attention to invasive brain implants that allow patients to control digital devices using their minds. The company is currently running a global clinical trial and is also busy preparing for its next product, Blindsight, which would restore vision to people with visual impairments. Neuralink’s visibility has helped accelerate similar efforts in China. Beijing last year classified brain-computer interfaces as a strategic sector and issued a roadmap calling for two or three globally competitive companies by 2030, as per the *Financial Times*. Since February last year, at least 10 clinical trials for invasive brain chips have launched in the country. NeuroXess recently reported that a paralyzed patient was able to control a computer cursor within five days of implantation. Founder Tiger Tao credited government support for helping shorten the path from research to trials. Investment activity has followed the policy push. Industry data show dozens of financing rounds for Chinese BCI startups over the past year, reflecting rising capital interest in the field. Ultimately, while Neuralink remains one of the most closely watched players globally, its momentum has clearly energized competitors abroad. ✕ Add to cart Buy now The post Elon Musk’s Neuralink sparks BCI race in China appeared first on TESLARATI. ### Related Stocks - [562600.CN - ChinaAMC CSI All Share Health Care Devices ETF](https://longbridge.com/en/quote/562600.CN.md) - [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md) - [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md) - [159883.CN - Maxwealth CSI All Share Medical Apparatus and Instruments ETF](https://longbridge.com/en/quote/159883.CN.md) - [516500.CN - ChinaAMC CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516500.CN.md) - [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md) - [159898.CN - China Merchants CSI All Share Medical Apparatus and Instruments ETF](https://longbridge.com/en/quote/159898.CN.md) - [XHE.US - SPDR S&P Health Equip](https://longbridge.com/en/quote/XHE.US.md) - [IHI.US - iShares US Medical Devices](https://longbridge.com/en/quote/IHI.US.md) - [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Finland's Modulight Q4 revenue rises, helped by growth in PPT business | Finland's Modulight reported a 21% year-over-year increase in Q4 revenue, reaching EUR 1.74 million, with an EBITDA of E | [Link](https://longbridge.com/en/news/276428080.md) | | 02:32 ETSobi Capital Markets Day 2026: Bringing brilliant ideas to life and building the next chapter with ambition to deliver SEK 55bn by 2030 | Sobi® (STO: SOBI) hosted its Capital Markets Day, announcing a strategy to achieve SEK 55bn in revenue by 2030, driven b | [Link](https://longbridge.com/en/news/276205979.md) | | BUZZ-Street View: Medtronic's early-stage product cycle strength evident, analysts say | Medtronicexceeded Wall Street's Q3 profit and revenue expectations, driven by strong heart device demand, but maintained | [Link](https://longbridge.com/en/news/276231714.md) | | Sulaiman Alhabib FY Profit 2,401.47 Mln Riyals | Dr Sulaiman Al Habib Medical Services Group Company SJSC :SULAIMAN ALHABIB FY NET PROFIT 2,401.47 MILLION RIYALSSULAIMAN | [Link](https://longbridge.com/en/news/275995976.md) | | Nanox to Showcase Nanox.ARC Live in Europe for First Time and Present New AI Capabilities at ECR 2026 \| NNOX Stock News | Nanox Imaging Ltd. will showcase its Nanox.ARC digital tomosynthesis system live in Europe for the first time at the Eur | [Link](https://longbridge.com/en/news/276128373.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.